BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (NYSE Alternext US:RGN) announced today that preliminary data from its Phase II clinical trial in Europe, evaluating the safety and wound-healing efficacy of RGN-137 for the treatment of patients with venous stasis ulcers, has been received and is being analyzed. RegeneRx will report data upon the completion of its analysis. The trial was conducted by Sigma-Tau Group, RegeneRx’s strategic partner in Europe and its largest stockholder.
